KALV vs NSC · rev $13.7M vs P/E 18, rev $6.46B
Kalvista Pharmaceuticals Inc (KALV) versus Norfolk Southern Corporation (NSC) — a side-by-side from cached financials, not a winner call.
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
Latest reported NSC revenue for 2026-06-30 was $6.46B. Net income was $1.28B. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
KALV currently screens at market cap $1.44B. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Not investment advice. Open the KALV and NSC stock pages for the full models.
Not investment advice.